Ganoderic acid A/DM-induced NDRG2 over-expression suppresses high-grade meningioma growth
N-myc downstream-regulated gene 2 (NDRG2) is down-regulated in grade-III meningioma [anaplastic meningioma (AM)] and associated with clinically aggressive behavior. Current therapies in the treatment of high-grade meningioma are lacking with limited success. This study aims to validate the effect of NDRG2-targeted therapy using structurally related bioactive triterpene compounds derived from the edible mushroom Ganoderma lucidum (ganoderic acid A:GA-A/ganoderic acid DM:GA-DM) in human AM in relevant pre-clinical models.
Tissue samples from the AM tumor regions of three human patients and control non-tumor samples were used to analyze the expression pattern of NDRG2. In vitro cell culture and in vivo cell-line-derived orthotopic xenograft animal models of AM were utilized to assess efficacy of treatment with GA-A/DM.
Downregulation of NDRG2 expression was observed in surgically resected high-grade meningiomas compared to normal brain. These results prompt us to use NDRG2-targeting agents GA-A/DM. In vitro results showed that 72-h treatments of 25 µM GA-A/DM induced AM cell death, upregulate NDRG2 protein expression, downregulate NDRG2 promoter methylation in meningioma cells as compared to azacitidine and decitabine, the most commonly used demethylating agents. Our results also demonstrated that GA-A/DM does not have any detrimental effect on normal human neurons and arachnoid cells. GA-A/DM promoted apoptotic factors (Bax) while suppressing MMP-9, p-P13K, p-AKT, p-mTOR, and Wnt-2 protein expression. RNAi-mediated knockdown of NDRG2 protein expression increased tumor proliferation, while forced expression of wt-NDRG2 decreased proliferation in an in vitro model. Magnetic resonance (MR) imaging and Hematoxylin (H&E) staining demonstrated gross reduction of tumor volume in GA-A/DM treated mice at 5 weeks when compared with saline-treated orthotopic AM xenografted controls. There was an overall decrease in tumor cell proliferation with increased survival in GA-A/DM-treated animals. Enzyme assays showed that GA-A/DM did not negatively impact hepatic function.
GA-A/DM may be a promising natural therapeutic reagent in the treatment of AM by suppressing growth via NDRG2 modulation and altering of intracellular signal pathways. We have shown it could potentially be an effective treatment for AM with decreased cellular proliferation in vitro, decreased tumor volume and increased survival in vivo.
KeywordsGanoderic acid A/DM Anaplastic meningioma (AM) NDRG2 Animal model
Conceived and designed the experiments: AD and DC. Analyzed the data: AD, MA, and DC. Wrote the first draft of the manuscript: AD and DC. Contributed to the writing of the manuscript: AD, MA, FH, SJP, SML, LI, AKV, WAV, and JLMS (all authors). Agree with manuscript results and conclusions: all authors. Jointly developed the structure and arguments for the paper: all authors. Made critical revisions and approved final version: AD and DC. All authors reviewed and approved of the final manuscript.
Completion of this project was made possible in part by the MUSC Neuroscience Institute Pilot Grants (2017-18), and Funds from the Department of Neurosurgery.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Subjects gave their written, informed consent to participate.
- 7.Yamamura A, Miura K, Karasawa H, Morishita K, Abe K, Mizuguchi Y, Saiki Y, Fukushige S, Kaneko N, Sase T, Nagase H, Sunamura M, Motoi F, Egawa S, Shibata C, Unno M, Sasaki I, Horii A. Suppressed expression of NDRG2 correlates with poorprognosis in pancreatic cancer. Biochem Biophys Res Commun. 2013;441(1):102–7.CrossRefGoogle Scholar
- 11.Yang Y, Zhou H, Liu W, Wu J, Yue X, Wang J, Quan L, Liu H, Guo L, Wang Z, Lian X, Zhang Q. Ganoderic acid A exerts antitumor activity against MDA-MB-231 human breast cancer cells by inhibiting the Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway. Oncol Lett. 2018;16(5):6515–21.PubMedPubMedCentralGoogle Scholar
- 14.Teekachunhatean S, Sadja S, Ampasavate C, Chiranthanut N, Rojanasthien N, Sangdee C. Pharmacokinetics of ganoderic acids a and f after oral administration of ling zhi preparation in healthy male volunteers. J Evid Based Complementary Altern Med. 2012;2012:780892.Google Scholar
- 17.Das A, Miller R, Lee P, Holden CA, Lindhorst SM, Jaboin J, Vandergrift WA 3rd, Banik NL, Giglio P, Varma AK, Raizer JJ, Patel SJ. A novel component from citrus, ginger, and mushroom family exhibits antitumor activity on human meningioma cells through suppressing the Wnt/β-catenin signaling pathway. Tumour Biol. 2015;36(9):7027–34.CrossRefGoogle Scholar
- 27.Das A, Henderson F Jr, Lowe S, Wallace GC 4th, Vandergrift WA 3rd, Lindhorst SM, Varma AK, Infinger LK, Giglio P, Banik NL, Patel SJ, Cachia D. Single agent efficacy of the HDAC inhibitor DATS in preclinical models of glioblastoma. Cancer Chemother Pharmacol. 2018;82(6):945–52.CrossRefGoogle Scholar
- 28.Wallace GCT, Haar CP, Vandergrift WA 3rd, Giglio P, Dixon-Mah YN, Varma AK, Ray SK, Patel SJ, Banik NL, Das A. Multi-targeted DATS prevents tumor progression and promotes apoptosis in ectopic glioblastoma xenografts in SCID mice via HDAC inhibition. J Neurooncol. 2013;114(1):43–50.CrossRefGoogle Scholar